Lincas Orvi (plant-derived remedy) Granules for solution preparation

Instructions for Lincas Orvi (plant-derived remedy) Granules for solution preparation

Composition Lincas Orvi

• willow bark — 750 mg
• adatode vascular leaves — 300 mg
• violets of fragrant leaves and flowers — 100 mg
• licorice root — 550 mg
• chinese leaf tea — 125 mg
• fennel — 75 mg
• ball leaf eucalyptus — 35 mg
• drug rhizome valerian with roots — 100 mg

Auxiliary substances:

• Levomentol 5 mg,
• cornstarch 20 mg,
• sucrose up to 5.6 mg.
• In granules with a taste of lemon additionally:
• lemon flavor concentrate Lemon Lime S-8946 0,056 ml.

Pharmacological effect Lincas Orvi:

It has expectorant, anti-inflammatory, mucolytic and antipyretic effects.

Pharmacokinetics:

Since the drug is a multicomponent plant drug, it is not possible to study its pharmacokinetics.

Testimony Lincas Orvi:

• Symptomatic therapy of acute respiratory viral infections (SARS), 
• fever (up to 38°C), headache, 
• nasal congestion, 
• swallowing sickness, 
• cough.

Contraindications for use Lincas Orvi:

Age up to 18 years;
increased individual sensitivity to drug components.
Special Instructions
The preparation includes sucrose, which should be taken into account when prescribing the drug to patients with diabetes mellitus and patients following a hypocaloric diet.

The use of ENT Lycas with anti-cough medicines and with drugs that reduce the formation of sputum is not recommended at the same time.

Use in children
The drug is contraindicated in children and adolescents under 18 years of age.

• Nosology Lincas Orvi (ICD codes)
• J02
• Acute pharyngitis
• J04
• Acute laryngitis and tracheitis
• J06.9
• Acute upper respiratory tract infection unspecified
• J15
• Bacterial pneumonia not classified elsewhere
• J20
• Acute bronchitis
• J31.2
• Chronic pharyngitis
• J37
• Chronic laryngitis and laryngotracheitis
• J42
• Chronic bronchitis unspecified
• R05
• Cough